Linzagolix for endometriosis-associated pain: key secondary efficacy endpoints from edelweiss 3, A phase 3, randomized, double-bind, placebo-controlled trial

Dolmans, Marie-Madeleine

Linzagolix for endometriosis-associated pain: key secondary efficacy endpoints from edelweiss 3, A phase 3, randomized, double-bind, placebo-controlled trial

Dolmans, Marie-Madeleine

(2023) World Endometriosis Society (WCE 2023) — Location: Edimbourg, Scotland (4.May.2023)

Files

No attached file found for this publication.

Details

Authors

Dolmans, Marie-MadeleineUCLouvain
Author

Affiliations

UCLouvainSSS/IREC/GYNE - Pôle de Gynécologie

Citations

APA
Chicago
FWB

Dolmans, M.-M. (2023). Linzagolix for endometriosis-associated pain: key secondary efficacy endpoints from edelweiss 3, A phase 3, randomized, double-bind, placebo-controlled trial. World Endometriosis Society (WCE 2023), Edimbourg, Scotland.